Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Lamellar ichthyosis

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare autosomal recessive congenital ichthyosis characterized by the presence of large scales all over the body without significant erythroderma.

ORPHA:313

Classification level: Disorder

Synonym(s):
  • LI

Source: PubMed ID 9545389 24397709

Prevalence: 1-9 / 1 000 000

Inheritance: Autosomal dominant, Autosomal recessive

Age of onset: Neonatal

ICD-10: Q80.2

ICD-11: EC20.02

OMIM: 242300 601277 604777 606545 612281 613943 146750 617574 617571

UMLS: C5848247

MeSH: D017490

GARD: 10803

MedDRA: 10023686

Summary
Epidemiology

It is the most common variant of autosomal recessive congenital ichthyosis (ARCI). Prevalence in Europe is estimated at approximately 1/100,000-1/300,000 individuals.

Clinical description

Newborns are often encased in a collodion membrane (taut, shiny, translucent membrane appearing as an extra skin layer) with ectropion and eclabium. Once the membrane has been shed (after one to two weeks), scales covering the whole body become apparent. In classic lamellar ichthyosis (LI), scales are large, dark and plate-like. Milder forms with lighter and thinner scales are possible. Contrarily to congenital ichthyosiform erythroderma (CIE), there is no significant erythroderma. Nevertheless, LI and CIE are the two extremities of the same spectrum, with many patients exhibiting intermediate phenotypes. Furthermore, patients' phenotypes may change over time or under treatment. Skin is usually itchy or painful (with cracks), mobility can be reduced due to skin stiffness over the joints, and cutaneous barrier function is impaired, which can result in increased transepidermal water loss and a proneness to dehydration. Other associated features include: persistent ectropion and associated eye complications (keratitis, corneal scarring), nail dystrophy, scarring alopecia, palmoplantar keratoderma, failure to thrive, short stature, hypohidrosis with heat intolerance, and impaired hearing (due to the accumulation of scales in the external ear).

Etiology

LI is a genetically heterogeneous disease within the disease spectrum of autosomal recessive congenital ichthyosis (ARCI) generally due to mutations in the genes TGM1, ABCA12, ALOX12B, and NIPAL4. Most mutations are found in the TGM1 gene encoding transglutaminase 1, involved in the formation of the epidermal cornified cell envelope. ABCA12 encodes an ATP-binding cassette (ABC) transporter, involved in lipid transport, ALOX12B and NIPAL4 encode arachidonate 12(R)-lipoxygenase and ichthyn respectively and are involved in lipid metabolism. There is no clear genotype-phenotype correlation. There also exists an autosomal dominant lamellar ichthyosis with palmoplantar keratoderma due to mutations in ASPRV1, which encodes a protease involved in Filaggrin processing.

Diagnostic methods

The diagnosis is based on the clinical appearance of the skin and can be confirmed by genetic testing. Histological features include orthohyperkeratosis, a normal to slightly widened stratum granulosum, acanthosis, and papillomatosis of the epidermis. Immunohistochemistry using antibodies directed against transglutaminase 1 or transglutaminase 1 enzyme activity measurement is available in some centers. Molecular testing (such as gene panel diagnosis) is possible in national reference laboratories.

Differential diagnosis

Differential diagnosis includes syndromic forms of ichthyosis, recessive X-linked ichthyosis and semidominant ichthyosis vulgaris, and CIE in case of erythroderma.

Antenatal diagnosis

Prenatal diagnosis is based on DNA analysis of amniocentesis and chorion villus sampling materials.

Genetic counseling

Genetic counseling should be offered to the affected families.

Management and treatment

Newborns presenting with collodion baby are usually admitted to a neonatal intensive care unit for 2 to 4 weeks. In later life, management is based on daily applications of emollients and/or keratolytics. Oral retinoids are useful in severe forms. Acitretin is the only retinoid approved by the European Medical Agency (EMA). Usually dosages of 0.5 mg/kg/day are sufficient. Doses should be maintained as low as 10-25 mg/day.

Prognosis

Prognosis is variable. During the neonatal period, there is a risk of sepsis and electrolyte imbalance. The disease often remains stable throughout life, with periods of exacerbation. Life expectancy is normal after the somewhat critical neonatal period. LI has a strong impact on quality of life due to altered physical appearance, troublesome symptoms, and the many constraints due to the disease and its treatment.

Last update: December 2022 - Expert reviewer(s): Dr Kira SÜßMUTH | ERN-Skin*

* European Reference Network

A summary on this disease is available in Français, Logo ERN Español, Logo ERN Deutsch, Logo ERN Italiano, Português, Logo ERN Nederlands Logo ERN Suomi, Polski
Detailed information

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

General public
Article for general public
Svenska (2017) - Socialstyrelsen
Guidelines
Emergency guidelines
Français (2018.pdf) - Orphanet Urgences
Anesthesia guidelines
English (2014) - Orphananesthesia
Čeština (2014) - Orphananesthesia
Clinical practice guidelines
Disease review articles
Clinical genetics review
English (2013.pdf) - Eur J Hum Genet
English (2023) - GeneReviews
Patient-Centered Outcome Measures (PCOMs)
Access questionnaires assessing quality of life in this disease (English)
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.